Találati lista | Tudóstér

001-es BibID:	BIBFORM127831
035-os BibID:	(scopus)85208142733 (wos)001348488500001
Első szerző:	Banach, Maciej
Cím:	2024 Recommendations on the Optimal Use of Lipid-Lowering Therapy in Established Atherosclerotic Cardiovascular Disease and Following Acute Coronary Syndromes : a Position Paper of the International Lipid Expert Panel (ILEP) / Banach Maciej, Reiner Zeljko, Surma Stanisaw, Bajraktari Gani, Bielecka-Dabrowa Agata, Bunc Matjazm Bytyci Ibadete, Ceska Richard, Cicero Arrigo F. G., Dudek Dariusz, Dyrbus Krzysztof, Fedacko Jan, Fras Zlatko, Gaita Dan, Gavish Dov, Gierlotka Marek, Gil Robert, Gouni-Berthold Ioanna, Jankowski Piotr, Járai Zoltán, Józwiak Jacek, Katsiki Niki, Latkovskis Gustavs, Magda Stefania Lucia, Margetic Eduard, Margoczy Roman, Mitchenko Olena, Durak-Nalbantic Azra, Ostadal Petr, Paragh Gyorgy, Petrulioniene Zaneta, Paneni Francesco, Pecin Ivan, Pella Daniel, Postadzhiyan Arman, Stoian Anca Pantea, Trbusic Matias, Udroiu Cristian Alexandru, Viigimaa Margus, Vinereanu Dragos, Vlachopoulos Charalambos, Vrablik Michal, Vulic Dusko, Penson Peter E., International Lipid Expert Panel (ILEP)
Dátum:	2024
ISSN:	0012-6667
Megjegyzések:	Atherosclerotic cardiovascular disease (ASCVD) and consequent acute coronary syndromes (ACS) are substantial contributors to morbidity and mortality across Europe. Fortunately, as much as two thirds of this disease's burden is modifiable, in particular by lipid-lowering therapy (LLT). Current guidelines are based on the sound premise that, with respect to low-density lipoprotein cholesterol (LDL-C), "lower is better for longer", and recent data have strongly emphasised the need for also "the earlier the better". In addition to statins, which have been available for several decades, ezetimibe, bempedoic acid (also as fixed dose combinations), and modulators of proprotein convertase subtilisin/kexin type 9 (PCSK9 inhibitors and inclisiran) are additionally very effective approaches to LLT, especially for those at very high and extremely high cardiovascular risk. In real life, however, clinical practice goals are still not met in a substantial proportion of patients (even in 70%). However, with the options we have available, we should render lipid disorders a rare disease. In April 2021, the International Lipid Expert Panel (ILEP) published its first position paper on the optimal use of LLT in post-ACS patients, which complemented the existing guidelines on the management of lipids in patients following ACS, which defined a group of "extremely high-risk" individuals and outlined scenarios where upfront combination therapy should be considered to improve access and adherence to LLT and, consequently, the therapy's effectiveness. These updated recommendations build on the previous work, considering developments in the evidential underpinning of combination LLT, ongoing education on the role of lipid disorder therapy, and changes in the availability of lipid-lowering drugs. Our aim is to provide a guide to address this unmet clinical need, to provide clear practical advice, whilst acknowledging the need for patient-centred care, and accounting for often large differences in the availability of LLTs between countries.
Tárgyszavak:	Orvostudományok Klinikai orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban folyóiratcikk Acute Coronary Syndrome Anticholesteremic Agents Atherosclerosis Cardiovascular Diseases Cholesterol, LDL Humans Hydroxymethylglutaryl-CoA Reductase Inhibitors Hypolipidemic Agents Practice Guidelines as Topic
Megjelenés:	Drugs. - 84 : 12 (2024), p. 1541-1577. -
További szerzők:	Reiner, Željko Surma, Stanisaw Bajraktari, Gani Bielecka-Dabrowa, Agata Bunc, Matjaz Bytyci, Ibadete Ceska, Richard Cicero, Arrigo F. G. Dudek, Darius Dyrbus, Krzysztof Fedacko, Jan Fras, Zlatko Gaita, Dan Gavish, Dov Gierlotka, Marek Gil, Robert Gouni-Berthold, Ioanna Jankowski, Piotr Járai Zoltán Józwiak, Jacek Katsiki, Niki Latkovskis, Gustavs Magda, Stefania Lucia Margetic, Eduard Margoczy, Roman Mitchenko, Olena Durak-Nalbantic, Azra Ostadal, Petr Paragh György (1953-) (belgyógyász) Petrulioniene, Zaneta Paneni, Francesco Pećin, Ivan Pella, Daniel Postadzhiyan, Arman Stoian, Anca Pantea Trbusic, Matias Udroiu, Cristian Alexandru Viigimaa, Margus Vinereanu, Dragos Vlachopoulos, Charalambos Vrablík, Michal Vulic, Dusko Penson, Peter E. International Lipid Expert Panel (ILEP)
Internet cím:	Szerző által megadott URL DOI Intézményi repozitóriumban (DEA) tárolt változat
Borító:
Saját polcon:

001-es BibID:	BIBFORM113310
035-os BibID:	(Scopus)85150079527 (WOS)000953520500001
Első szerző:	Rizzo, Manfredi
Cím:	Nutraceutical approaches to non-alcoholic fatty liver disease (NAFLD) : A position paper from the International Lipid Expert Panel (ILEP) / Rizzo Manfredi, Colletti Alessandro, Penson Peter E., Katsiki Niki, Mikhailidis Dimitri P., Toth Peter P., Gouni-Berthold Ioanna, Mancini John, Marais David, Moriarty Patrick, Ruscica Massimiliano, Sahebkar Amirhossein, Vinereanu Dragos, Cicero Arrigo Francesco Giuseppe, Banach Maciej, International Lipid Expert Panel (ILEP)
Dátum:	2023
ISSN:	1043-6618
Megjegyzések:	Non-Alcoholic Fatty Liver Disease (NAFLD) is a common condition affecting around 10?25% of the general adult population, 15% of children, and even > 50% of individuals who have type 2 diabetes mellitus. It is a major cause of liver-related morbidity, and cardiovascular (CV) mortality is a common cause of death. In addition to being the initial step of irreversible alterations of the liver parenchyma causing cirrhosis, about 1/6 of those who develop NASH are at risk also developing CV disease (CVD). More recently the acronym MAFLD (Metabolic Associated Fatty Liver Disease) has been preferred by many European and US specialists, providing a clearer message on the metabolic etiology of the disease. The suggestions for the management of NAFLD are like those recommended by guidelines for CVD prevention. In this context, the general approach is to prescribe physical activity and dietary changes the effect weight loss. Lifestyle change in the NAFLD patient has been supplemented in some by the use of nutraceuticals, but the evidence based for these remains uncertain. The aim of this Position Paper was to summarize the clinical evidence relating to the effect of nutraceuticals on NAFLD-related parameters. Our reading of the data is that whilst many nutraceuticals have been studied in relation to NAFLD, none have sufficient evidence to recommend their routine use; robust trials are required to appropriately address efficacy and safety.
Tárgyszavak:	Orvostudományok Klinikai orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban folyóiratcikk Adult Cardiovascular Diseases Child Diabetes Mellitus, Type 2 Dietary Supplements Humans Lipids Liver Cirrhosis Non-alcoholic Fatty Liver Disease
Megjelenés:	Pharmacological Research. - 189 (2023), p. 1-8. -
További szerzők:	Colletti, Alessandro Penson, Peter E. Katsiki, Niki Mikhailidis, Dimitri P. Tóth Péter P. Gouni-Berthold, Ioanna Mancini, John Marais, David Moriarty, Patrick M. Ruscica, Massimiliano Sahebkar, Amirhossein Vinereanu, Dragos Cicero, Arrigo F. G. Banach, Maciej Paragh György (1953-) (belgyógyász) International Lipid Expert Panel (ILEP)
Internet cím:	Szerző által megadott URL DOI Intézményi repozitóriumban (DEA) tárolt változat
Borító:
Saját polcon:

001-es BibID:	BIBFORM107036
035-os BibID:	(scopus)85109445846 (wos)000686978200008
Első szerző:	Ruscica, Massimiliano
Cím:	Impact of nutraceuticals on markers of systemic inflammation : Potential relevance to cardiovascular diseases - A position paper from the International Lipid Expert Panel (ILEP) / Ruscica Massimiliano, Penson Peter E., Ferri Nicola, Sirtori Cesare R., Pirro Matteo, Mancini G. B. John, Sattar Naveed, Toth Peter P., Sahebkar Amirhossein, Lavie Carl J., Wong Nathan D., Banach Maciej, International Lipid Expert Panel (ILEP)
Dátum:	2021
ISSN:	0033-0620
Tárgyszavak:	Orvostudományok Klinikai orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban folyóiratcikk
Megjelenés:	Progress In Cardiovascular Diseases. - 67 (2021), p. 40-52. -
További szerzők:	Penson, Peter E. Ferri, Nicola Sirtori, Cesare R. Pirro, Matteo Mancini, G. B. John Sattar, Naveed Tóth Péter P. Sahebkar, Amirhossein Lavie, Carl J. Wong, Nathan D. Banach, Maciej Paragh György (1953-) (belgyógyász) International Lipid Expert Panel (ILEP)
Internet cím:	Szerző által megadott URL DOI Intézményi repozitóriumban (DEA) tárolt változat
Borító:
Saját polcon: